// App-Quantinova.ai

OP0030 (2021) : TREATMENT OF NON-BIOLOGIC-DMARD-IR PSA PATIENTS WITH UPADACITINIB OR ADALIMUMAB RESULTS IN THE MODULATION OF DISTINCT FUNCTIONAL PATHWAYS: PROTEOMICS ANALYSIS OF THE SELECT-PSA 1 PHASE 3 STUDY

Researchers

Presenter

  • T. Sornasse

Principal Investigators

  • J. Anderson

  • K. Kato

  • A. Lertratanakul

  • C. T. Ritchlin

  • I. McInnes

Medical Centers

  • AbbVie, Precision Medicine Immunology, Redwood City, United States of America

  • AbbVie Immunology Clinical Development, North Chicago, United States of America

  • University of Rochester, Allergy/Immunology and Rheumatology, Rochester, United States of America

  • University of Glasgow, Medical Veterinary and Life Sciences, Glasgow, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

  • Adalimumab

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved